Operating Segments (Tables)

6 Months Ended

Jun. 30, 2017

Operating Segments [Abstract]

Summary of operating segments

	Three Months Ended June 30,
	2017			2016
Contract Revenue
Vaccines/BioDefense	$	990,971		$	3,160,050
BioTherapeutics		-			-
Total	$	990,971		$	3,160,050
Income (Loss) from Operations
Vaccines/BioDefense	$	197,270		$	734,120
BioTherapeutics		(1,574,261	)		(668,260	)
Corporate		(939,838	)		(1,075,818	)
Total	$	(2,316,829	)	$	(1,009,958	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,611		$	10,041
BioTherapeutics		8,077			10,564
Corporate		933			2,223
Total	$	18,621		$	22,828
Other Income (Expense), Net
Corporate	$	5,231		$	917,183
Share-Based Compensation
Vaccines/BioDefense	$	14,973		$	24,223
BioTherapeutics		22,827			30,985
Corporate		56,247			145,065
Total	$	94,047		$	200,273

	Six Months Ended June 30,
	2017			2016
Contract Revenue
Vaccines/BioDefense	$	2,321,855		$	5,791,037
BioTherapeutics		-			-
Total	$	2,321,855		$	5,791,037
Income (Loss) from Operations
Vaccines/BioDefense	$	333,870		$	1,052,111
BioTherapeutics		(2,601,816	)		(1,914,682	)
Corporate		(1,787,073	)		(2,053,092	)
Total	$	(4,055,019	)	$	(2,915,663	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	19,380		$	20,060
BioTherapeutics		17,644			20,996
Corporate		2,647			4,380
Total	$	39,671		$	45,436
Other Income (Expense), Net
Corporate	$	9,984		$	1,673,455
Share-Based Compensation
Vaccines/BioDefense	$	32,971		$	52,229
BioTherapeutics		72,597			65,817
Corporate		135,106			218,638
Total	$	240,674		$	336,684

	As of June 30, 2017		As of December 31, 2016
Identifiable Assets
Vaccines/BioDefense	$	783,821	$	1,297,986
BioTherapeutics		37,320		49,422
Corporate		5,952,481		8,919,698
Total	$	6,773,622	$	10,267,105